Shares of IXICO plc (LON:IXI – Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 11.66 and traded as low as GBX 10.64. IXICO shares last traded at GBX 10.64, with a volume of 8,574 shares.
IXICO Stock Performance
The company has a debt-to-equity ratio of 3.32, a quick ratio of 4.90 and a current ratio of 2.85. The stock has a market cap of £10.10 million, a PE ratio of -5.89, a PEG ratio of -0.38 and a beta of 0.86. The company’s 50-day moving average price is GBX 11.41 and its two-hundred day moving average price is GBX 11.66.
IXICO (LON:IXI – Get Free Report) last released its earnings results on Tuesday, December 9th. The company reported GBX (1.85) EPS for the quarter. IXICO had a negative net margin of 31.10% and a negative return on equity of 19.14%. On average, equities research analysts forecast that IXICO plc will post -289.3584879 EPS for the current year.
About IXICO
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.
By unlocking valuable insights into drug safety and efficacy, IXICO has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) managing and analysing neurological clinical trials.
Featured Stories
- Five stocks we like better than IXICO
- Trump’s NEW Executive Order – BIG Changes Coming to Retirement Accounts
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- New Banking Law #1582 Could Unlock $21 Trillion for Americans
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for IXICO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IXICO and related companies with MarketBeat.com's FREE daily email newsletter.
